Clinical Trial

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Protocol Amendment History 3 changes
notable Trial sites expanded: 23 -> 27 locations 2026-07-14
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-03
notable Trial sites reduced: 27 -> 23 locations 2026-06-03
Trial Details
NCT Number NCT05787587
Lead Sponsor IDEAYA Biosciences
Collaborators: Merck Sharp & Dohme LLC
Conditions Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC) +1 more
Enrollment 216 participants
Start Date 2023-04-18
Primary Completion 2026-10 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-13